Fund moves
6.2%Stake · was 6.2%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AKTS · NASDAQ · Pharmaceutical Preparations
Aktis Oncology (AKTS) · oqro.io/stocks/AKTS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$16.10−0.21 (−1.29%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
No open-market purchase by an insider of Aktis Oncology is on record in SEC filings since 2006.
No open-market sale by an insider of Aktis Oncology (AKTS) was filed with the SEC in the last 90 days.
No trade in Aktis Oncology (AKTS) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−28.1% (−$6.30) from Jan 9, 2026 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $22.40 on Jan 9, 2026 to $16.10 on Nov 18, 2026 (−28.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 6 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Boston, Ma.
Last 12 months
Not enough history
Market value
$895M
Short interest: 4.43M shares sold short (8.0% of shares outstanding), +2.6% vs the previous count, 16.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$3.9M
+147.3% vs the same quarter a year earlier
Free cash flow, last 12 months
−$26.8M
This quarter −$26.8M, a year earlier −$17.2M
Net debt
—
Debt —, cash $68.3M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
8 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
8 tracked managers disclosed the same change for Q1 2026. Among this manager's largest new positions for Q1 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Against the S&P 500 over the year
Since Jan 9, 2026, AKTS is down 28.1% and the index fund is up 5.2%: 33 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AKTS moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.